Inaphaea Co-Marketing Agreement

Inaphaea Co

Inaphaea is pleased to confirm the execution of a co-marketing agreement (the "Agreement") with US contract research organisation Netoids Rx Laboratories LLC, doing business as Spanios LLC ("Spanios"), to provide Inaphaea's high throughput drug screening services using its Patient Derived Cells ("PDC") as a precursor to Spanios's proprietary Patient Derived Tumoroids ("PDT").

Inaphaea and Spanios will be entitled to a percentage of service royalties on relevant contract introduced by the respective party. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "This deal with Spanios is the first co-marketing arrrangment for Inaphaea in the US and demonstrates the synergy of our Patient Derived Cell approach for rapid and economic screening of larger numbers of drug candidates before transferring lead candidates into Spanios's lower throughput but higher complexity, ex-vivo models."

Mark Eccleston, CEO of ValiRx commented "We are excited to be working with a highly innovative partner like Spanios. Bringing therapies to market faster requires better models for screening drugs to deliver more accurate and translatable results. Inaphaea has focussed on the early stage of this process where, typically, larger numbers of candidates need to be refined for screening in disease relevant models. We can then pass on the best candidates to Spanios for testing in their organoid platform."

Bhuvanesh Dave, PhD, Co-Founder and CEO of Spanios, commented "The partnership with Inaphaea is a perfect fit for our joint goal of accelerating drug development to bring therapies to patients faster. Combining Inaphaea's higher throughput approach to candidate selection with our versatile three-dimensional PDT drug testing platform, COMPASS (Custom Organoid Modelling Platform for Accurate & Speedy Solutions) which is capable of recapitulating tumor microenvironment (TME) including features of oxygenation and immunocompetence, we can combine the best of both approaches for advancing discovery and development pipeline."